Vision Improvement for Patients With Age-Related Macular Degeneration

NCT ID: NCT06198452

Last Updated: 2024-09-05

Basic Information

• Recruitment Status: NOT_YET_RECRUITING
• Clinical Phase: NA
• Total Enrollment: 200 participants
• Study Classification: INTERVENTIONAL
• Study Start Date: 2025-01-01
• Study Completion Date: 2027-06-30

Brief Summary

This study is being conducted to assess the safety and efficacy of the VIS, LLC (VIS) Opti-K Low Vision Aid Device and treatment to provide vision improvement to patients with age-related macular degeneration.

Detailed Description

This study is being conducted to assess the safety and efficacy of the VIS, LLC (VIS) Opti-K Low Vision Aid Device and treatment to provide vision improvement to patients with age-related macular degeneration.

Conditions

Macular Degeneration

Study Design

• Allocation Method: NA
• Intervention Model: SINGLE_GROUP
• Primary Study Purpose: TREATMENT
• Blinding Strategy: NONE

Study Groups

Vision Improvement

Group Type: EXPERIMENTAL

Vision Improvement

Intervention Type: PROCEDURE

Laser Vision Improvement for Patients with Age-Related Macular Degeneration

Interventions

Vision Improvement

Laser Vision Improvement for Patients with Age-Related Macular Degeneration

Intervention Type: PROCEDURE

Eligibility Criteria

Inclusion Criteria

Subjects who meet all of the following criteria are candidates for this study:

1. Male or Female

2. Any race

3. Patient is at least 50 years old.

4. Patient has diagnosed end stage dry or wet age-related macular degeneration in one or both eyes, as verified by a complete ocular examination.

5. Patient is pseudophakic or is phakic with no clinically significant cataract in eye(s) to be treated.

6. Patient has manifest refraction, spherical equivalent (MRSE) between -1.50 D to 1.50 D in eye(s) to be treated.

7. Patient has moderate to severe vision impairment due to age-related macular degeneration with best spectacle-corrected distance visual acuity (CDVA) of 20/80 or worse (decimal less than or equal to 0.25; logMAR ≥ 0.60).in the better eye.

8. Patient has CDVA of 20/400 or better (decimal greater than or equal to 0.05; logMAR ≤ 1.30) in the worse eye.

9. Patient is not a contact lens (CL) wearer.

10. Patient is willing and able to comply with all examinations.

11. Patient must be competent to sign an informed consent form before study entry.

Exclusion Criteria

Subjects who meet any of the following criteria are to be excluded from this study:

1. Corneal disease or corneal disorder in either eye.

2. Pathological retinal morphology in either eye that completely affects the entire 10° (3 mm diameter) of the retina centered on the foveola.

3. Gonzalez-Markowitz chart Potential Visual Acuity (PVA) in the eye to be treated that is not improved by at least four lines compared to CDVA;

4. Increased IOP (above 20 mm Hg), glaucoma or history of glaucoma;

5. Previous corneal surgery in the eye to be treated; and

6. Presence or history of any other condition or finding that, in the opinion of the investigator, makes the patient unsuitable as a candidate for study participation or that may confound the outcome of the study.

• Minimum Eligible Age: 50 Years
• Maximum Eligible Age: 100 Years
• Eligible Sex: ALL
• Accepts Healthy Volunteers: Yes

Sponsors

VIS, Inc.

INDUSTRY

Sponsor Role: lead

Responsible Party

Responsibility Role: SPONSOR

Central Contacts

Michael Berry, PhD

Role: CONTACT

mberry177@gmail.com

8318691384

Other Identifiers

VIS #001

Identifier Type: -

Identifier Source: org_study_id